Patents by Inventor Per Sauerberg

Per Sauerberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Oral Dosing of GLP-1 Compounds
    Publication number: 20260083678
    Abstract: The present invention relates to improved uses of GLP-1 peptides in oral therapy.
    Type: Application
    Filed: December 3, 2025
    Publication date: March 26, 2026
    Inventors: Flemming S. Nielsen, Per Sauerberg
  • Oral dosing of GLP-1 compounds
    Patent number: 12514822
    Abstract: The present invention relates to improved uses of glucagon-like peptide 1 (GLP-1) peptides in oral therapy.
    Type: Grant
    Filed: April 28, 2025
    Date of Patent: January 6, 2026
    Assignee: Novo Nordisk A/S
    Inventors: Flemming S. Nielsen, Per Sauerberg
  • Oral Dosing of GLP-1 Compounds
    Publication number: 20250262159
    Abstract: The present invention relates to improved uses of GLP-1 peptides in oral therapy.
    Type: Application
    Filed: April 28, 2025
    Publication date: August 21, 2025
    Inventors: Flemming S. Nielsen, Per Sauerberg
  • Oral Dosing of GLP-1 Compounds
    Publication number: 20250213485
    Abstract: The present invention relates to improved uses of GLP-1 peptides in oral therapy.
    Type: Application
    Filed: January 13, 2025
    Publication date: July 3, 2025
    Inventors: Flemming S. Nielsen, Per Sauerberg
  • GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES
    Publication number: 20250122226
    Abstract: This invention relates to glucose-sensitive albumin-binding diboron conjugates. More particularly the invention provides novel diboron compounds, and in particular diboronate or diboroxole compounds, useful as intermediate compounds for the synthesis of diboron conjugates.
    Type: Application
    Filed: December 18, 2024
    Publication date: April 17, 2025
    Inventors: Thomas Kruse, Mikael Kofod-Hansen, Martin Werner Borchsenius Muenzel, Henning Thoegersen, Per Sauerberg, Jakob Ewald, Carsten Behrens, Thomas Hoeg-Jensen, Vojtech Balsanek, Zuzana Drobnakova, Ladislav Droz, Miroslav Havranek, Vladislav Kotek, Milan Stengl, Ivan Snajdr, Hana Drusanova
  • Oral dosing of GLP-1 compounds
    Patent number: 12239739
    Abstract: The present invention relates to improved uses of glucagon-like peptide-1 (GLP-1) peptides in oral therapy.
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: March 4, 2025
    Assignee: Novo Nordisk A/S
    Inventors: Flemming S. Nielsen, Per Sauerberg
  • Glucose-sensitive albumin-binding derivatives
    Patent number: 12227528
    Abstract: This invention relates to glucose-sensitive albumin-binding diboron conjugates. More particularly the invention provides novel diboron compounds, and in particular diboronate or diboroxole compounds, useful as intermediate compounds for the synthesis of diboron conjugates.
    Type: Grant
    Filed: June 16, 2023
    Date of Patent: February 18, 2025
    Assignee: Novo Nordisk A/S
    Inventors: Thomas Kruse, Mikael Kofod-Hansen, Martin Werner Borchsenius Muenzel, Henning Thoegersen, Per Sauerberg, Jakob Ewald, Carsten Behrens, Thomas Hoeg-Jensen, Vojtech Balsanek, Zuzana Drobnakova, Ladislav Droz, Miroslav Havranek, Vladislav Kotek, Milan Stengl, Ivan Snajdr, Hana Drusanova
  • SOLID COMPOSITIONS COMPRISING A GLP-1 AGONIST AND A SALT OF N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID
    Publication number: 20240277817
    Abstract: The present invention relates to solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and their use in medicine.
    Type: Application
    Filed: April 23, 2024
    Publication date: August 22, 2024
    Inventors: Per Sauerberg, Simon Bjerregaard, Flemming Seier Nielsen
  • GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES
    Publication number: 20230331745
    Abstract: This invention relates to glucose-sensitive albumin-binding diboron conjugates. More particularly the invention provides novel diboron compounds, and in particular diboronate or diboroxole compounds, useful as intermediate compounds for the synthesis of diboron conjugates.
    Type: Application
    Filed: June 16, 2023
    Publication date: October 19, 2023
    Inventors: Thomas Kruse, Mikael Kofod-Hansen, Martin Werner Borchsenius Muenzel, Henning Thoegersen, Per Sauerberg, Jakob Ewald Rasmussen, Carsten Behrens, Thomas Hoeg-Jensen, Vojtech Balsanek, Zuzana Drobnakova, Ladislav Droz, Miroslav Havranek, Vladislav Kotek, Milan Stengl, Ivan Snajdr, Hana Drusanova
  • SOLID COMPOSITIONS COMPRISING A GLP-1 AGONIST AND A SALT OF N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID
    Publication number: 20230302092
    Abstract: The present invention relates to solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and their use in medicine.
    Type: Application
    Filed: April 4, 2023
    Publication date: September 28, 2023
    Inventors: Per Sauerberg, Simon Bjerregaard, Flemming Seier Nielsen
  • Glucose-sensitive albumin-binding derivatives
    Patent number: 11767332
    Abstract: This invention relates to glucose-sensitive albumin-binding diboron conjugates. More particularly the invention provides novel diboron compounds, and in particular diboronate or diboroxole compounds, useful as intermediate compounds for the synthesis of diboron conjugates.
    Type: Grant
    Filed: October 13, 2021
    Date of Patent: September 26, 2023
    Assignee: Novo Nordisk A/S
    Inventors: Thomas Kruse, Mikael Kofod-Hansen, Martin Werner Borchsenius Muenzel, Henning Thoegersen, Per Sauerberg, Jakob Ewald Rasmussen, Carsten Behrens, Thomas Hoeg-Jensen, Vojtech Balsanek, Zuzana Drobnakova, Ladislav Droz, Miroslav Havranek, Vladislav Kotek, Milan Stengl, Ivan Snajdr, Hana Drusanova
  • GLP-1 derivatives and uses thereof
    Patent number: 11572398
    Abstract: The invention relates to a derivative of a GLP-1 analogue of a general Formula I, which derivative comprises a side chain attached to a Lys residue at position 34, 35, 36, 37, or 38 of the GLP-1 analogue, which side chain comprises a Branched linker, a 1st and a 2nd Protractor selected from C18 diacid, C20 diacid, and sulfonic acid C16, and at least one Linker element-1 incorporating ethylene glycol units. Linker element-1 may be incorporated in an optional Pre-linker, and/or in a 1st or 2nd Post-linker. The invention also relates to novel GLP-1 analogues, novel side chain intermediate products and their manufacture and use to prepare derivatives of biologically active peptides and proteins, as well as pharmaceutical compositions and medical uses of the analogues and derivatives. The derivatives have very long half-lives while maintaining a satisfactory potency, which makes them potentially suitable for once-monthly administration.
    Type: Grant
    Filed: November 26, 2015
    Date of Patent: February 7, 2023
    Assignee: Novo Nordisk A/S
    Inventors: Per Sauerberg, Jacob Kofoed
  • Glucose sensitive insulins and uses thereof
    Patent number: 11541122
    Abstract: The present invention provides glucose sensitive insulin derivatives comprising a macrocycle, a glucose mimetic and human insulin or an analogue thereof, and their pharmaceutical use. Furthermore, the invention relates to pharmaceutical compositions comprising such glucose sensitive insulin derivatives, and to the use of such compounds for the treatment or prevention of medical conditions relating to diabetes.
    Type: Grant
    Filed: September 18, 2019
    Date of Patent: January 3, 2023
    Inventors: Thomas Hoeg-Jensen, Alice Ravn Madsen, Thomas Kruse, Per Sauerberg, Anthony Murray, Andrew Michael Chapman, Anthony Peter Davis
  • SOLID COMPOSITIONS COMPRISING A GLP-1 AGONIST AND A SALT OF N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID
    Publication number: 20220313786
    Abstract: The present invention relates to solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and their use in medicine.
    Type: Application
    Filed: June 3, 2022
    Publication date: October 6, 2022
    Inventors: Per Sauerberg, Simon Bjerregaard, Flemming Seier Nielsen
  • Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists
    Patent number: 11420929
    Abstract: Phenoxy acetic acids and phenyl propionic acids and their use in improving mitochondrial energy output in a subject are provided herein. The present compounds are activators of PPAR? and may be useful for treating conditions mediated by the same.
    Type: Grant
    Filed: March 9, 2021
    Date of Patent: August 23, 2022
    Assignee: VTV THERAPEUTICS LLC
    Inventors: Per Sauerberg, Pavel Pihera, Zdenek Polivka, Miroslav Havranek, Ingrid Pettersson, John Patrick Mogensen
  • Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid
    Patent number: 11382957
    Abstract: The present invention relates to solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and their use in medicine.
    Type: Grant
    Filed: February 19, 2021
    Date of Patent: July 12, 2022
    Assignee: Novo Nordisk A/S
    Inventors: Per Sauerberg, Simon Bjerregaard, Flemming Seier Nielsen
  • GLUCOSE SENSITIVE INSULIN DERIVATIVES
    Publication number: 20220184184
    Abstract: The present invention relates to novel insulin derivatives and their use in the treatment or prevention of medical conditions relating to diabetes. The insulin derivatives are glucose sensitive and display glucose-sensitive albumin binding. The invention also relates to novel intermediates. Finally, the invention provides a pharmaceutical composition comprising the insulin derivatives of the invention and the use of such a composition in the treatment or prevention of medical conditions relating to diabetes.
    Type: Application
    Filed: March 27, 2020
    Publication date: June 16, 2022
    Inventors: Thomas Hoeg-Jensen, Carsten Behrens, Emiliano Clo, Martin Werner Borchsenius Muenzel, Per Sauerberg, Thomas Kruse, Jane Spetzler, Ulrich Sensfuss, Claudia Ulrich Hjoerringgaard, Henning Thoegersen, Vojtech Balsanek, Zuzana Drobnakova, Ladislav Droz, Miroslav Havranek, Vladislav Kotek, Milan Stengl, Ivan Snajdr, Hana Drusanova
  • GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES
    Publication number: 20220081451
    Abstract: This invention relates to glucose-sensitive albumin-binding diboron conjugates. More particularly the invention provides novel diboron compounds, and in particular diboronate or diboroxole compounds, useful as intermediate compounds for the synthesis of diboron conjugates.
    Type: Application
    Filed: October 13, 2021
    Publication date: March 17, 2022
    Inventors: Thomas Kruse, Mikael Kofod-Hansen, Martin Werner Borchsenius Muenzel, Henning Thoegersen, Per Sauerberg, Jakob Ewald Rasmussen, Carsten Behrens, Thomas Hoeg-Jensen, Vojtech Balsanek, Zuzana Drobnakova, Ladislav Droz, Miroslav Havranek, Vladislav Kotek, Milan Stengl, Ivan Snajdr, Hana Drusanova
  • Pharmaceutical Composition for Oral GLP-1 Administration Comprising a Tablet Core and Immediate Release Coating
    Publication number: 20220062184
    Abstract: The present invention relates to pharmaceutical compositions comprising a tablet core and an immediate release coating, wherein said tablet core comprises a GLP-1 peptide and an absorption enhancer, as well as uses thereof.
    Type: Application
    Filed: November 19, 2021
    Publication date: March 3, 2022
    Inventors: Pernille Nybo, Flemming S. Nielsen, Birgitte Nissen, Per Sauerberg, Rikke B. Skyggebjerg
  • GLUCOSE SENSITIVE INSULINS AND USES THEREOF
    Publication number: 20220047708
    Abstract: The present invention provides glucose sensitive insulin derivatives comprising a macrocycle, a glucose mimetic and human insulin or an analogue thereof, and their pharmaceutical use. Furthermore, the invention relates to pharmaceutical compositions comprising such glucose sensitive insulin derivatives, and to the use of such compounds for the treatment or prevention of medical conditions relating to diabetes.
    Type: Application
    Filed: September 18, 2019
    Publication date: February 17, 2022
    Inventors: Thomas Hoeg-Jensen, Alice Ravn Madsen, Thomas Kruse, Per Sauerberg, Anthony Murray, Andrew Michael Chapman, Anthony Peter Davis